Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TARS

Tarsus Pharmaceuticals Inc

Feb 06 • 04:00PM ET

64.62

+2.63 4.24 %

Healthcare • Biotechnology • USA • NASD

Peers: XENE FOLD RDUS VKTX SRPT AXSM BTAI PRTA APLT PTCT

| Held by: VTI IWM VXF IWO IBB VTWO SCHA PJP VHT IHE

Index	RUT	P/E	-	EPS (ttm)	-2.01	Insider Own	7.72%	Shs Outstand	42.45M	Perf Week	0.12%
Market Cap	2.74B	Forward P/E	33.61	EPS next Y	1.92	Insider Trans	-2.76%	Shs Float	39.17M	Perf Month	-17.24%
Enterprise Value	2.42B	PEG	-	EPS next Q	-0.07	Inst Own	103.30%	Short Float	13.70%	Perf Quarter	-5.25%
Income	-81.16M	P/S	7.49	EPS this Y	53.08%	Inst Trans	-5.49%	Short Ratio	9.85	Perf Half Y	34.77%
Sales	366.10M	P/B	8.19	EPS next Y	233.49%	ROA	-17.82%	Short Interest	5.37M	Perf YTD	-21.08%
Book/sh	7.89	P/C	6.83	EPS next 5Y	-	ROE	-28.35%	52W High	85.25 -24.20%	Perf Year	13.49%
Cash/sh	9.47	P/FCF	-	EPS past 3/5Y	-65.92% -67.97%	ROIC	-19.44%	52W Low	38.51 67.80%	Perf 3Y	312.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.49% -	Gross Margin	93.26%	Volatility	4.79% 4.33%	Perf 5Y	67.24%
Dividend TTM	-	EV/Sales	6.62	EPS Y/Y TTM	47.21%	Oper. Margin	-23.88%	ATR (14)	3.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.25	Sales Y/Y TTM	182.44%	Profit Margin	-22.17%	RSI (14)	34.90	Recom	1.30
Dividend Gr. 3/5Y	- -	Current Ratio	4.29	EPS Q/Q	51.59%	SMA20	-6.56%	Beta	0.59	Target Price	90.10
Payout	-	Debt/Eq	0.25	Sales Q/Q	146.68%	SMA50	-14.98%	Rel Volume	1.47	Prev Close	61.99
Employees	323	LT Debt/Eq	0.25	Earnings	Nov 04 AMC	SMA200	9.72%	Avg Volume	544.50K	Price	64.62
IPO	Oct 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.14% 3.01%	Trades		Volume	799,575	Change	4.24%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$100
Nov-20-25	Initiated	Mizuho	Outperform	$100
Jun-02-25	Resumed	Oppenheimer	Outperform	$75
May-27-25	Resumed	H.C. Wainwright	Buy	$72
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Feb-02-26 12:27PM	Will Declining Medical Customers Affect Cigna's Q4 Earnings? (Zacks)
Jan-26-26 09:35AM	Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) (Zacks)
Jan-13-26 11:40AM	BMRN or TARS: Which Is the Better Value Stock Right Now? (Zacks)
Nov-24-25 04:30PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-05-25 05:05PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire)
12:04AM	Loading…
12:04AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-04-25 05:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Nov-03-25 07:31AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-28-25 05:00PM	Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire)
Oct-09-25 09:27AM	Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 06:41AM	Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Aug-27-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 06:33PM	3 Biotech Catalysts Present Major Opportunity (MarketBeat)
Aug-15-25 10:04AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily)
02:48PM	Loading…
Aug-14-25 02:48PM	Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point. (Investor's Business Daily)
Aug-06-25 06:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.15%
04:05PM	Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-05-25 09:48AM	Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result (GuruFocus.com)
Jul-30-25 05:00PM	Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
May-29-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:45AM	Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-08-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-05-25 06:04PM	Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts (Insider Monkey)
May-02-25 03:17AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com) -5.84%
May-01-25 09:37PM	Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? (Zacks)
10:00AM	Loading…
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-24-25 05:00PM	Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (GlobeNewswire)
11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks)
08:31AM	Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting (GlobeNewswire)
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-12-25 09:49PM	Tarsus Announces Pricing of Upsized $125.0 Million Public Offering (GlobeNewswire)
04:12PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Mar-06-25 05:00PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire) +6.66%
Feb-26-25 02:13AM	Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-25-25 08:40AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
01:31AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 05:00PM	Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 (GlobeNewswire)
Jan-30-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-20-25 03:31PM	Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Jan-14-25 09:35AM	Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround (Zacks) -5.72%
Jan-13-25 08:30AM	Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care (GlobeNewswire) -10.76%
Dec-26-24 10:30AM	How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run (Investor's Business Daily)
Dec-04-24 09:55AM	Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet (Zacks)
Nov-18-24 09:55AM	Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade (Zacks)
Nov-14-24 02:15AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-13-24 05:30PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
08:30AM	Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors (GlobeNewswire)
Nov-07-24 10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Nov-06-24 04:30PM	Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 (GlobeNewswire)
Nov-05-24 08:30AM	Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer (GlobeNewswire)
Oct-30-24 06:39AM	Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-24 08:30AM	Tarsus Launches Your Mitey Problem, the First Direct-to-Consumer TV Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% (GlobeNewswire)
Oct-09-24 05:56PM	Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ... (GuruFocus.com)
Sep-25-24 05:00PM	Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 (GlobeNewswire)
Aug-28-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference (GlobeNewswire)
Aug-08-24 09:56PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +13.72%
06:05PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
Jul-29-24 04:30PM	Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
May-29-24 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference (GlobeNewswire) -8.86% +8.70%
12:48PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:06AM	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating (MT Newswires)
03:49AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-08-24 08:58PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
May-06-24 09:55AM	Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect? (Zacks)
May-01-24 05:00PM	Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 (GlobeNewswire) +6.59%
Apr-23-24 08:30AM	Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon (GlobeNewswire)
Apr-09-24 07:35AM	5 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 09:55AM	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know (Zacks)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why (Zacks)
Mar-06-24 09:55AM	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% (Zacks)
Mar-05-24 04:30PM	Tarsus to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Tarsus Introduces Mite Party Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis (GlobeNewswire)
Mar-01-24 12:07AM	Tarsus Announces Pricing of $100.0 Million Public Offering (GlobeNewswire)
Feb-29-24 04:37PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Feb-28-24 12:00PM	Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy (Zacks)
09:58AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:13PM	Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +18.28%
06:34AM	Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
06:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Feb-22-24 08:00AM	Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease (GlobeNewswire)
Feb-20-24 05:00PM	Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 (GlobeNewswire)
Jan-31-24 05:00PM	Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference (GlobeNewswire) +6.17%
Jan-30-24 04:06AM	Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last? (Zacks)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Whitfield Dianne C.	Chief Human Resources Officer	Jan 02 '26	Sale	80.67	15,565	1,255,684	23,393	Jan 06 04:05 PM
Whitfield Dianne C.	Officer	Jan 02 '26	Proposed Sale	81.38	15,565	1,266,680		Jan 02 11:22 AM
Azamian Bobak R.	President/CEO and Board Chair	Dec 24 '25	Sale	82.51	6,000	495,089	857,991	Dec 30 04:26 PM
BOBAK AZAMIAN	OFFICER	Dec 24 '25	Proposed Sale	82.51	6,000	495,089		Dec 29 12:22 PM
Whitfield Dianne C.	Chief Human Resources Officer	Dec 16 '25	Sale	80.10	7,397	592,500	38,958	Dec 18 04:09 PM
LINK WILLIAM J PHD	Director	Dec 15 '25	Sale	81.43	12,500	1,017,816	128,832	Dec 17 04:07 PM
LINK WILLIAM J PHD	Director	Dec 15 '25	Sale	81.07	10,446	846,862	0	Dec 17 04:07 PM
Lin Elizabeth Yeu	Chief Medical Officer	Dec 16 '25	Sale	79.50	2,078	165,201	21,941	Dec 17 04:07 PM
Lin Elizabeth Yeu	Officer	Dec 16 '25	Proposed Sale	79.50	2,078	165,202		Dec 16 03:12 PM
Whitfield Dianne C.	Officer	Dec 16 '25	Proposed Sale	80.10	7,397	592,500		Dec 16 10:11 AM
William Link	Director	Dec 15 '25	Proposed Sale	81.02	10,446	846,340		Dec 15 04:38 PM
WILLIAM J LINK	DIRECTOR	Dec 15 '25	Proposed Sale	81.42	12,500	1,017,800		Dec 15 04:08 PM
Azamian Bobak R.	President/CEO and Board Chair	Sep 24 '25	Sale	55.37	6,000	332,220	812,106	Sep 26 04:08 PM
Bobak Azamian Living Trust	Officer	Sep 24 '25	Proposed Sale	55.37	6,000	332,208		Sep 24 04:57 PM
LINK WILLIAM J PHD	Director	Sep 08 '25	Sale	57.00	27,116	1,545,612	143,332	Sep 10 05:03 PM
LINK WILLIAM J PHD	Director	Sep 08 '25	Proposed Sale	57.01	27,116	1,546,000		Sep 08 04:19 PM
Azamian Bobak R.	President/CEO and Board Chair	Aug 11 '25	Sale	50.00	6,000	300,000	818,106	Aug 13 04:32 PM
Azamian Bobak R.	Officer	Aug 11 '25	Proposed Sale	50.00	6,000	300,000		Aug 11 12:43 PM
Farrow Jeffrey S	See Remarks	Jun 17 '25	Sale	40.42	13,608	550,035	36,704	Jun 18 04:07 PM
Farrow Jeffrey S	Officer	Jun 17 '25	Proposed Sale	40.42	13,608	550,088		Jun 17 04:14 PM
Lin Elizabeth Yeu	Chief Medical Officer	Jun 16 '25	Sale	41.08	1,006	41,326	7,694	Jun 17 04:07 PM
Lin Elizabeth Yeu	Officer	Jun 16 '25	Proposed Sale	41.07	1,006	41,321		Jun 16 03:07 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 09 '25	Sale	43.76	17,500	765,800	47,557	Jun 11 04:50 PM
Mottiwala Aziz	Officer	Jun 09 '25	Proposed Sale	44.74	17,500	782,950		Jun 09 10:21 AM
Azamian Bobak R.	President/CEO and Board Chair	Mar 24 '25	Sale	50.00	6,000	300,000	824,106	Mar 26 04:47 PM
Azamian Bobak R.	Officer	Mar 24 '25	Proposed Sale	50.00	6,000	300,000		Mar 24 05:35 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '25	Sale	46.29	3,643	168,634	71,979	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 20 '25	Sale	50.11	3,365	168,620	65,057	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 19 '25	Sale	47.40	3,557	168,602	68,422	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 20 '25	Sale	50.11	2,435	122,018	79,682	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '25	Sale	46.29	2,605	120,585	84,660	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 19 '25	Sale	47.40	2,543	120,538	82,117	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 18 '25	Sale	46.29	3,341	154,655	58,057	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 19 '25	Sale	47.40	3,261	154,571	54,796	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 20 '25	Sale	50.11	3,084	154,539	51,712	Mar 20 09:49 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '25	Sale	46.29	2,315	107,161	50,751	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 20 '25	Sale	50.11	2,137	107,085	46,355	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 19 '25	Sale	47.40	2,259	107,077	48,492	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 20 '25	Sale	50.11	8,534	427,639	53,635	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 19 '25	Sale	47.40	8,551	405,317	62,169	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '25	Sale	46.29	7,131	330,094	70,720	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 19 '25	Sale	47.40	1,254	59,440	23,617	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 18 '25	Sale	46.29	1,284	59,436	24,871	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 20 '25	Sale	50.11	1,186	59,430	22,431	Mar 20 09:48 PM
Whitfield Dianne C.	Officer	Mar 20 '25	Proposed Sale	50.11	2,137	107,093		Mar 20 04:35 PM
Farrow Jeffrey S	Officer	Mar 20 '25	Proposed Sale	50.11	1,186	59,435		Mar 20 04:30 PM
Mottiwala Aziz	Officer	Mar 20 '25	Proposed Sale	50.11	3,365	168,632		Mar 20 04:29 PM
Wahl Bryan	Officer	Mar 20 '25	Proposed Sale	50.11	3,084	154,550		Mar 20 04:21 PM
Neervannan Seshadri	Officer	Mar 20 '25	Proposed Sale	50.11	2,435	122,026		Mar 20 04:18 PM
Azamian Bobak R.	Officer	Mar 20 '25	Proposed Sale	50.11	8,534	427,669		Mar 20 04:11 PM
Neervannan Seshadri	Officer	Mar 19 '25	Proposed Sale	47.40	2,543	120,536		Mar 19 03:27 PM
Wahl Bryan	Officer	Mar 19 '25	Proposed Sale	47.40	3,261	154,569		Mar 19 03:24 PM
Azamian Bobak R.	Officer	Mar 19 '25	Proposed Sale	47.40	8,551	405,311		Mar 19 03:23 PM
Whitfield Dianne C.	Officer	Mar 19 '25	Proposed Sale	47.40	2,259	107,075		Mar 19 03:22 PM
Farrow Jeffrey S	Officer	Mar 19 '25	Proposed Sale	47.40	1,254	59,439		Mar 19 03:12 PM
Mottiwala Aziz	Officer	Mar 19 '25	Proposed Sale	47.40	3,557	168,599		Mar 19 03:12 PM
Neervannan Seshadri	Officer	Mar 18 '25	Proposed Sale	46.28	2,605	120,571		Mar 18 04:31 PM
Wahl Bryan	Officer	Mar 18 '25	Proposed Sale	46.28	3,341	154,637		Mar 18 04:26 PM
Mottiwala Aziz	Officer	Mar 18 '25	Proposed Sale	46.28	3,643	168,614		Mar 18 04:26 PM
Whitfield Dianne C.	Officer	Mar 18 '25	Proposed Sale	46.28	2,315	107,149		Mar 18 04:20 PM
Azamian Bobak R.	Officer	Mar 18 '25	Proposed Sale	46.28	7,131	330,055		Mar 18 04:15 PM
Farrow Jeffrey S	Officer	Mar 18 '25	Proposed Sale	46.28	1,284	59,429		Mar 18 04:12 PM
Goldberg Andrew D.	Director	Mar 07 '25	Option Exercise	12.89	7,000	90,230	13,350	Mar 11 04:01 PM

Open in Screener

ALXO

Alx Oncology Holdings Inc

Feb 06 • 04:00PM ET

2.05

-0.01 -0.49 %

Healthcare • Biotechnology • USA • NASD

ALXO Alx Oncology Holdings Inc daily Stock Chart

Peers: IOVA KPTI SRRK XNCR TVRD AFMD TGTX BHVN ZLAB BPMC

| Held by: VTI VXF VHT BTEC AVSC AVTM

Index	-	P/E	-	EPS (ttm)	-2.03	Insider Own	29.16%	Shs Outstand	53.58M	Perf Week	17.82%
Market Cap	268.95M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	26.84%	Shs Float	38.41M	Perf Month	73.73%
Enterprise Value	223.93M	PEG	-	EPS next Q	-0.36	Inst Own	34.95%	Short Float	2.83%	Perf Quarter	62.70%
Income	-108.01M	P/S	-	EPS this Y	29.36%	Inst Trans	-6.04%	Short Ratio	3.05	Perf Half Y	190.86%
Sales	0.00M	P/B	2.45	EPS next Y	51.71%	ROA	-80.47%	Short Interest	1.09M	Perf YTD	81.42%
Book/sh	0.84	P/C	4.44	EPS next 5Y	35.57%	ROE	-118.95%	52W High	2.41 -14.94%	Perf Year	65.32%
Cash/sh	0.46	P/FCF	-	EPS past 3/5Y	-7.67% -32.29%	ROIC	-199.54%	52W Low	0.40 407.43%	Perf 3Y	-77.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.20% 12.92%	Perf 5Y	-97.47%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	31.98%	Oper. Margin	-	ATR (14)	0.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	70.62	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	2.40	EPS Q/Q	29.07%	SMA20	32.34%	Beta	0.46	Target Price	3.33
Payout	-	Debt/Eq	0.35	Sales Q/Q	-	SMA50	43.72%	Rel Volume	1.96	Prev Close	2.06
Employees	80	LT Debt/Eq	0.21	Earnings	Nov 07 BMO	SMA200	93.15%	Avg Volume	356.71K	Price	2.05
IPO	Jul 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.81% -	Trades		Volume	699,815	Change	-0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-13-25	Initiated	Jefferies	Buy	$4
Mar-06-25	Upgrade	Jefferies	Hold → Buy	$2 → $3
Dec-19-24	Downgrade	Jefferies	Buy → Hold	$12 → $2
Mar-08-24	Downgrade	Stifel	Buy → Hold	$10 → $14
Dec-08-23	Upgrade	Jefferies	Hold → Buy	$8 → $18
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$65 → $25
Sep-30-21	Initiated	Stifel	Buy	$106
May-05-21	Resumed	Credit Suisse	Outperform	$98
Apr-26-21	Resumed	Credit Suisse	Outperform	$98
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy	$100
Aug-11-20	Initiated	Piper Sandler	Overweight	$55
Aug-11-20	Initiated	Jefferies	Buy	$50
Aug-11-20	Initiated	Credit Suisse	Outperform	$53
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight	$64

Show Previous Ratings

Jan-30-26 08:30AM	ALX Oncology Announces Pricing of Underwritten Offering (GlobeNewswire) +10.83%
08:15AM	New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer (GlobeNewswire)
Jan-15-26 05:17PM	ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference (MarketBeat) -9.02%
Jan-08-26 11:00AM	ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.08%
08:30AM	ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 (GlobeNewswire)
08:00AM	Loading…
Dec-07-25 08:00AM	ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting (GlobeNewswire)
Nov-18-25 11:00AM	ALX Oncology to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-08-25 02:05AM	ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... (GuruFocus.com)
Nov-07-25 08:15AM	ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +16.95%
Oct-30-25 08:30AM	ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting (GlobeNewswire)
Oct-23-25 12:30PM	ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference (GlobeNewswire) +8.70%
Oct-14-25 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? (Zacks) -8.11%
Oct-03-25 09:05AM	ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) +14.14%
Sep-12-25 08:30AM	ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer (GlobeNewswire) -10.17%
Aug-29-25 12:00PM	ALX Oncology to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
08:00AM	Loading…
Aug-19-25 08:00AM	ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors (GlobeNewswire) -8.37%
Aug-13-25 03:13AM	ALX Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com) +7.40%
Aug-12-25 04:05PM	ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 08:00AM	ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire) +12.68%
May-30-25 08:00AM	ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event (GlobeNewswire)
May-13-25 08:00AM	ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 (GlobeNewswire) +10.52%
May-08-25 08:30AM	ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-25 08:00AM	ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-28-25 07:51AM	ALX Oncologys CD47-blocker and Keytruda combo fails in two Phase II trials (Clinical Trials Arena)
Apr-25-25 01:10PM	ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma (GlobeNewswire) -9.87%
09:00AM	ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints (GlobeNewswire)
Apr-07-25 08:00AM	ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate (GlobeNewswire)
Mar-20-25 09:55AM	ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
01:27PM	Loading…
Mar-07-25 01:27PM	Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday (Insider Monkey) -19.08%
Mar-06-25 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +25.96%
Mar-05-25 08:00AM	ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event (GlobeNewswire)
Feb-27-25 08:00AM	ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire)
Feb-18-25 08:00AM	ALX Oncology to Host Virtual R&D Day on March 5, 2025 (GlobeNewswire) +7.27%
Jan-23-25 02:44PM	ALX Oncology Shares Drop 15% Following Positive Phase 2 (GuruFocus.com) -9.44%
08:00AM	ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer (GlobeNewswire)
Jan-22-25 04:01PM	ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules (GlobeNewswire) +9.09%
09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
08:00AM	ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors (GlobeNewswire)
Jan-21-25 05:00PM	ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI (GlobeNewswire) -5.17%
Jan-07-25 09:40AM	Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 08:57AM	Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' (Investing.com) -19.57%
Dec-18-24 08:00AM	ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-12-24 08:00AM	ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 (GlobeNewswire) -5.96%
Dec-10-24 09:00AM	ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer (GlobeNewswire) -8.14%
Nov-26-24 08:00AM	ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-21-24 09:35AM	ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +6.61%
Nov-14-24 08:00AM	ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-07-24 04:00PM	ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-24 08:00AM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire)
Nov-01-24 05:30PM	ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 (GlobeNewswire)
Oct-10-24 07:04PM	Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc (GuruFocus.com) -11.11% +6.94%
Sep-09-24 08:00AM	ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +9.95%
Sep-04-24 08:00AM	ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi (GlobeNewswire)
Aug-08-24 04:05PM	ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-24 04:01PM	ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors (GlobeNewswire) -6.55%
Aug-01-24 09:05AM	Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients (Benzinga) -41.67%
06:52AM	ALX Oncologys evorpacept shows potential in Phase II gastric cancer trial (Clinical Trials Arena)
Jul-31-24 04:01PM	ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer (GlobeNewswire) -11.93%
05:30AM	ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Jun-17-24 11:00AM	Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO) (GuruFocus.com) -8.32%
Jun-03-24 09:35AM	Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround (Zacks) -15.71%
Jun-02-24 10:00AM	ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer (GlobeNewswire)
May-29-24 09:00AM	ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) -10.91%
May-16-24 02:54AM	Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares (GuruFocus.com)
May-14-24 09:55AM	Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet (Zacks)
May-10-24 02:21PM	ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ... (GuruFocus.com)
May-09-24 10:57PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024 (InvestorPlace)
04:00PM	ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 05:38PM	Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing (MT Newswires) -5.41%
May-07-24 09:00AM	ALX Oncology Appoints Allison Dillon as Chief Business Officer (GlobeNewswire) +11.28%
Apr-30-24 09:00AM	ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer (GlobeNewswire)
Apr-24-24 10:00AM	ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-11-24 09:30AM	ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study (Zacks) +11.04%
Apr-09-24 05:30PM	ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ( R/R B-NHL ) (GlobeNewswire)
Apr-06-24 01:33AM	ALX Oncology Holdings Inc (ALXO) Insider Sells Shares (GuruFocus.com)
Mar-08-24 03:48PM	ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer (Benzinga) -6.34%
Mar-07-24 10:53PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023 (InvestorPlace) +9.95%
10:41PM	ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending (GuruFocus.com)
04:03PM	ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting (GlobeNewswire)
Jan-03-24 08:00AM	ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 04:21PM	7 Small-Cap Stocks That Wall Street Loves for Good Reason (InvestorPlace) +18.04%
Nov-13-23 04:47PM	ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) +8.08%
04:05PM	ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire) +6.35%
Oct-10-23 04:05PM	ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +16.24%
Oct-06-23 04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks) +27.38%
Oct-05-23 10:58AM	Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More (Zacks)
08:00AM	ALX Oncology Announces Pricing of Public Offering (GlobeNewswire)
Oct-04-23 04:10PM	ALX Oncology Announces Proposed Public Offering (GlobeNewswire) -15.05%
11:39AM	ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data (Zacks)
Oct-03-23 11:15AM	Why ALX Oncology Stock Is Skyrocketing Today (Motley Fool) +56.13%
09:36AM	Midday movers: McCormick Airbnb, Point Biopharma and more (Investing.com)
06:00AM	ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Oct-02-23 04:05PM	ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Sep-06-23 08:00AM	ALX Oncology Realigns Executive Leadership Team (GlobeNewswire) +6.37%
Aug-31-23 07:00AM	ALX Oncology Announces September Investor Conference Participation (GlobeNewswire)

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOODMAN COREY S	Director	Feb 02 '26	Buy	1.57	3,184,713	4,999,999	8,453,038	Feb 04 04:15 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jan 06 '26	Sale	1.11	3,925	4,357	88,273	Jan 07 04:30 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Sep 17 '25	Buy	1.08	71,163	76,892	305,121	Sep 18 04:23 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Sep 16 '25	Buy	1.07	21,070	22,461	233,958	Sep 18 04:23 PM
Shantharam Harish	Chief Financial Officer	Aug 18 '25	Buy	0.78	75,000	58,402	75,000	Aug 20 04:02 PM
Pinto Shelly	SVP, FINANCE AND CAO	Aug 15 '25	Sale	0.64	611	391	89,198	Aug 19 04:12 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Aug 15 '25	Sale	0.64	2,382	1,525	212,888	Aug 19 04:09 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jul 07 '25	Sale	0.45	2,011	905	86,809	Jul 08 04:37 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jun 30 '25	Sale	0.43	1,532	659	88,820	Jul 01 04:22 PM
Pinto Shelly	SVP, FINANCE AND CAO	Feb 19 '25	Sale	1.15	550	633	87,352	Feb 21 04:25 PM
Pons Jaume	PRESIDENT & CSO	Feb 19 '25	Sale	1.15	1,326	1,525	579,388	Feb 21 04:23 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	1.15	2,159	2,483	170,270	Feb 21 04:20 PM

TARS

Tarsus Pharmaceuticals Inc

ALXO

Alx Oncology Holdings Inc

Upgrade your FINVIZ experience